Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Acute kidney injury warning: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, including semaglutide. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of RYBELSUS® in patients reporting severe adverse gastrointestinal reactions.
eGFR=estimated glomerular filtration rate
Prescribe RYBELSUS® for patients not reaching their A1C target on metformin and lifestyle modifications, including those with compelling need to2:
ADA=American Diabetes Association